This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
vesicular stomatitis | 504 |
stomatitis virus | 455 |
influenza virus | 188 |
infected cells | 180 |
protein synthesis | 138 |
respiratory syndrome | 129 |
host cell | 120 |
cell lines | 118 |
hela cells | 109 |
virus infection | 101 |
type i | 97 |
antiviral activity | 97 |
immune responses | 95 |
ebola virus | 93 |
neutralizing antibodies | 74 |
ebov gp | 72 |
west nile | 71 |
recombinant vesicular | 70 |
viral mrnas | 70 |
plasma membrane | 66 |
enveloped viruses | 65 |
ifit mice | 65 |
virus replication | 65 |
vsv infection | 64 |
nile virus | 62 |
virus glycoprotein | 61 |
syndrome coronavirus | 61 |
amino acid | 60 |
vero cells | 60 |
pseudotyped virus | 57 |
viral envelope | 57 |
room temperature | 56 |
cell surface | 56 |
vaccinia virus | 55 |
cell culture | 54 |
rvsv vectors | 54 |
severe acute | 54 |
acute respiratory | 54 |
host protein | 54 |
cellular mrnas | 53 |
immunodeficiency virus | 53 |
neutralizing antibody | 52 |
virus particles | 52 |
spike protein | 52 |
virus type | 51 |
vectors expressing | 51 |
cell line | 51 |
viral rna | 50 |
viral replication | 50 |
gp pseudotyped | 49 |
cells infected | 49 |
antiviral activities | 49 |
herpes simplex | 49 |
gene expression | 48 |
aug codon | 48 |
host mrnas | 48 |
treated cells | 47 |
vaccinated mice | 47 |
immune response | 46 |
vaccine vectors | 45 |
human immunodeficiency | 45 |
fever virus | 44 |
viral proteins | 44 |
i ifn | 43 |
monoclonal antibodies | 43 |
influenza viruses | 43 |
vsv replication | 42 |
simplex virus | 42 |
leukemia virus | 41 |
mammalian cells | 41 |
viral infection | 41 |
middle east | 39 |
neutralization assay | 39 |
cotton rats | 39 |
cord uid | 39 |
rna polymerase | 39 |
doc id | 39 |
described previously | 39 |
measles virus | 38 |
previously described | 38 |
acid sphingomyelinase | 38 |
avian influenza | 38 |
porcine reproductive | 38 |
east respiratory | 38 |
hemorrhagic fever | 37 |
viral mrna | 37 |
cell entry | 36 |
er buds | 36 |
viral protein | 36 |
epithelial cells | 36 |
envelope proteins | 36 |
virus entry | 35 |
congo hemorrhagic | 35 |
recombinant vsv | 35 |
amino acids | 35 |
well plates | 34 |
export complexes | 34 |
syndrome virus | 34 |
golgi complex | 34 |
membrane fusion | 33 |
wt mice | 33 |
cell fusion | 33 |
bhk cells | 32 |
positive control | 32 |
transmembrane domain | 32 |
cap binding | 31 |
host translation | 31 |
lentiviral vectors | 31 |
tetherin antagonism | 30 |
murine leukemia | 30 |
host shutoff | 29 |
pseudotyped viruses | 29 |
pseudotyped hiv | 29 |
viral glycoproteins | 29 |
days post | 29 |
wt vsv | 29 |
sindbis virus | 29 |
endoplasmic reticulum | 29 |
vsv xn | 29 |
polysome association | 29 |
positive cells | 29 |
matrix protein | 29 |
protein expression | 29 |
stomatitis viruses | 28 |
virus vectors | 28 |
negative control | 28 |
neutralization test | 28 |
vaccine vector | 28 |
mdck cells | 27 |
virus envelope | 27 |
cytoplasmic tail | 27 |
structural proteins | 27 |
aug codons | 27 |
rvsv vector | 27 |
rna virus | 27 |
transcriptional activity | 27 |
cells expressing | 26 |
viral genome | 26 |
antibody responses | 26 |
viral entry | 26 |
intercat ifn | 26 |
host proteins | 26 |
membrane proteins | 26 |
live ebov | 26 |
body weight | 26 |
treated virions | 25 |
lipid bilayer | 25 |
rna viruses | 25 |
viral infections | 24 |
target cells | 24 |
cellular immune | 24 |
thermo fisher | 24 |
prok treated | 24 |
based assay | 24 |
replication competent | 24 |
tumor cells | 24 |
cell types | 24 |
sarcoma virus | 24 |
pseudotyped vsv | 24 |
previous studies | 23 |
performed using | 23 |
vsv rna | 23 |
virus mrnas | 23 |
insect cells | 23 |
recombinant vsvs | 23 |
mosaic virus | 23 |
inhibitory effect | 23 |
serum samples | 23 |
monoclonal antibody | 23 |
viral translation | 23 |
nucleotide sequence | 23 |
culture medium | 22 |
secondary structure | 22 |
proteolytic cleavage | 22 |
mrna cap | 22 |
tissue culture | 22 |
fusion protein | 22 |
binding protein | 22 |
cov infection | 22 |
virus glycoproteins | 22 |
envelope protein | 22 |
antibody titers | 22 |
animal models | 22 |
electron microscopy | 22 |
mm tris | 22 |
highly pathogenic | 22 |
sialic acid | 22 |
ifnar mice | 22 |
gfp expression | 21 |
pseudotyped vectors | 21 |
plaque assay | 21 |
molecular weight | 21 |
based vaccine | 21 |
weight loss | 21 |
fisher scientific | 21 |
nonhuman primates | 21 |
initiation factor | 21 |
envelope glycoprotein | 21 |
cotton rat | 21 |
retroviral vectors | 21 |
high levels | 20 |
serial dilutions | 20 |
mediated antiviral | 20 |
bovine serum | 20 |
antibody response | 20 |
sendai virus | 20 |
neutralization assays | 20 |
vector expressing | 20 |
semliki forest | 20 |
membrane protein | 20 |
cell responses | 20 |
present study | 20 |
western blot | 20 |
transduction efficiency | 20 |
infectious virus | 20 |
open reading | 20 |
nervous system | 20 |
dependent manner | 20 |
central nervous | 19 |
current study | 19 |
clinical trials | 19 |
first time | 19 |
com scientificreports | 19 |
virus rna | 19 |
surface proteins | 19 |
leader sequence | 19 |
coronavirus spike | 19 |
transfected cells | 19 |
virus assembly | 19 |
viral particles | 19 |
cell death | 19 |
test using | 19 |
infectious diseases | 19 |
post infection | 19 |
using vsv | 19 |
attenuated vesicular | 18 |
day pi | 18 |
protein kinase | 18 |
uninfected cells | 18 |
cytopathic effect | 18 |
mouse model | 18 |
lethal challenge | 18 |
significant differences | 18 |
dmem containing | 18 |
gene delivery | 18 |
determine whether | 18 |
pfu ml | 18 |
detected using | 18 |
expression vector | 18 |
reading frames | 18 |
single dose | 18 |
kindly provided | 18 |
animal cells | 18 |
forming units | 18 |
results indicate | 18 |
per well | 18 |
tetherin expression | 18 |
taken together | 18 |
vsv virions | 18 |
goat anti | 18 |
envelope glycoproteins | 18 |
feline ifn | 18 |
forest virus | 18 |
sars coronavirus | 17 |
three times | 17 |
cellular mrna | 17 |
control group | 17 |
virus expressing | 17 |
disease virus | 17 |
start site | 17 |
cell membrane | 17 |
virus infectivity | 17 |
reaction mixture | 17 |
final concentration | 17 |
reading frame | 17 |
reporter gene | 17 |
guinea pigs | 17 |
golgi apparatus | 17 |
whole virions | 17 |
whether doxorubicin | 17 |
viral gene | 17 |
emc virus | 17 |
oligomer formation | 17 |
sucrose gradients | 17 |
control groups | 17 |
results demonstrate | 17 |
signaling pathway | 17 |
neutralisation assay | 17 |
mers gfp | 17 |
virus titers | 17 |
pseudotypes bearing | 17 |
gene therapy | 17 |
expression levels | 17 |
upstream aug | 17 |
antiviral effect | 17 |
virus production | 16 |
virus vaccine | 16 |
virus neutralisation | 16 |
stranded rna | 16 |
infected rn | 16 |
prime boost | 16 |
washed twice | 16 |
translation initiation | 16 |
ebov neutralisation | 16 |
graphpad prism | 16 |
expression plasmids | 16 |
live virus | 16 |
green fluorescent | 16 |
highly attenuated | 16 |
cov neutralizing | 16 |
animal model | 16 |
fluorescent protein | 16 |
i interferon | 16 |
statistically significant | 16 |
may also | 16 |
neutralisation assays | 16 |
independent experiments | 16 |
host range | 16 |
coding sequence | 16 |
baculovirus vectors | 16 |
column chromatography | 16 |
gold particles | 16 |
host cells | 16 |
antibody titer | 16 |
buffered saline | 16 |
buds per | 15 |
viral titers | 15 |
rna replicates | 15 |
total number | 15 |
important role | 15 |
statistical significance | 15 |
restriction sites | 15 |
gp gp | 15 |
mg ml | 15 |
nipah virus | 15 |
protease inhibitor | 15 |
cytoplasmic domain | 15 |
fusion activity | 15 |
viral spread | 15 |
cd cd | 15 |
mg kg | 15 |
rabbit anti | 15 |
trypsin treatment | 15 |
mediated immune | 15 |
vectors pseudotyped | 15 |
latently infected | 15 |
dromedary camels | 15 |
viral vectors | 15 |
vaccine protects | 15 |
recombinant feifn | 15 |
type vsv | 15 |
gxxxg motif | 15 |
promoted ripa | 15 |
rous sarcoma | 15 |
luciferase activity | 14 |
novel coronavirus | 14 |
pathogenic avian | 14 |
innate immune | 14 |
antiviral agents | 14 |
containing fbs | 14 |
fetal bovine | 14 |
influenza virions | 14 |
cell protein | 14 |
surface glycoprotein | 14 |
two different | 14 |
cell lysates | 14 |
nucleocapsid protein | 14 |
autographa californica | 14 |
resistant oligomer | 14 |
sigmodon hispidus | 14 |
sialic acids | 14 |
protective immune | 14 |
flow cytometry | 14 |
serially diluted | 14 |
specific antibody | 14 |
coronavirus infection | 14 |
spectrum antiviral | 14 |
specific antibodies | 14 |
doxorubicin inhibits | 14 |
ripa activity | 14 |
challenge infection | 14 |
respiratory syncytial | 14 |
ifn signaling | 14 |
infectious vsv | 14 |
creative commons | 14 |
epithelial cell | 14 |
error bars | 14 |
genomic rna | 14 |
total cytoplasmic | 14 |
complete protection | 14 |
syncytial virus | 14 |
mice immunized | 14 |
associated reads | 14 |
virus strains | 14 |
also inhibited | 14 |
ng ml | 14 |
strand rna | 13 |
animal care | 13 |
western blotting | 13 |
three independent | 13 |
expression plasmid | 13 |
newly synthesized | 13 |
human glioblastoma | 13 |
pseudoparticle neutralization | 13 |
vsv vrp | 13 |
human cells | 13 |
er membrane | 13 |
rna synthesis | 13 |
intact cells | 13 |
gg ml | 13 |
rabies virus | 13 |
gene transfer | 13 |
also showed | 13 |
metabolic labeling | 13 |
vsv genome | 13 |
approved drugs | 13 |
resulting residue | 13 |
bat cell | 13 |
pbs containing | 13 |
stem cells | 13 |
dk services | 13 |
determined using | 13 |
virus particle | 13 |
using live | 13 |
glioma cells | 13 |
transcription unit | 13 |
immune system | 13 |
vaccine development | 13 |
host mrna | 13 |
cancer stem | 13 |
gel electrophoresis | 13 |
vaccine based | 13 |
significantly higher | 13 |
ribosomal subunits | 13 |
significant difference | 13 |
transcription promoter | 13 |
live attenuated | 13 |
infected wt | 13 |
cellular proteins | 13 |
cell viability | 13 |
attenuated rvsv | 12 |
authentic sars | 12 |
cov spike | 12 |
replication cycle | 12 |
culture supernatant | 12 |
messenger rna | 12 |
airway epithelial | 12 |
binding factor | 12 |
saudi arabia | 12 |
encephalitis virus | 12 |
viral genes | 12 |
initiation sites | 12 |
terminator codon | 12 |
previous study | 12 |
washed three | 12 |
viral membrane | 12 |
culture supernatants | 12 |
post transfection | 12 |
guinea pig | 12 |
glycosylation sites | 12 |
complemented vsv | 12 |
cells transfected | 12 |
prrsv olot | 12 |
cell proteases | 12 |
investigate whether | 12 |
vsv pseudotypes | 12 |
expressing cells | 12 |
viral surface | 12 |
vsv particles | 12 |
time points | 12 |
sense rna | 12 |
pseudotyped lentiviral | 12 |
erk signaling | 12 |
exclusion zone | 12 |
hepatitis virus | 12 |
renal epithelial | 12 |
results suggest | 12 |
sucrose cushion | 12 |
antiviral response | 12 |
golgi retention | 12 |
translational machinery | 12 |
gene encoding | 12 |
table i | 12 |
negative controls | 12 |
fold serial | 12 |
virus challenge | 12 |
vaccine candidates | 12 |
zoonotic viruses | 12 |
promote ripa | 12 |
golgi exclusion | 12 |
secondary antibodies | 12 |
virus matrix | 12 |
kidney cells | 11 |
reverse genetics | 11 |
protease inhibitors | 11 |
specific immune | 11 |
proteins identified | 11 |
packaging system | 11 |
protect mice | 11 |
protective efficacy | 11 |
feline leukemia | 11 |
hispidus cell | 11 |
live mers | 11 |
like particles | 11 |
medium containing | 11 |
human sera | 11 |
standard plaque | 11 |
virus groups | 11 |
attenuated vsv | 11 |
infected group | 11 |
binding domain | 11 |
lysis buffer | 11 |
feline interferon | 11 |
cell monolayers | 11 |
mm edta | 11 |
human tetherin | 11 |
cells grown | 11 |
recombinant baculovirus | 11 |
binding proteins | 11 |
based neutralization | 11 |
resident proteins | 11 |
biosafety level | 11 |
analyzed using | 11 |
strongly inhibited | 11 |
protects mice | 11 |
lethal dose | 11 |
bars indicate | 11 |
virus recombinants | 11 |
antiviral action | 11 |
data suggest | 11 |
previously reported | 11 |
silica gel | 11 |
vsv vector | 11 |
chromatography using | 11 |
expressing hiv | 11 |
primary antibodies | 11 |
two proteins | 11 |
doxorubicin treatment | 11 |
inhibited vsv | 11 |
caspase activity | 11 |
vsv vectors | 11 |
laboratory animals | 11 |
mouse igg | 11 |
increased polysome | 11 |
treated mice | 11 |
haemorrhagic fever | 11 |
virus mrna | 11 |
neutralization tests | 11 |
cells showed | 11 |
sucrose gradient | 11 |
first aug | 11 |
coat protein | 11 |
term protection | 11 |
new jersey | 11 |
gel column | 10 |
specific cell | 10 |
vaccinated animals | 10 |
neuronal necrosis | 10 |
antiviral state | 10 |
empty vector | 10 |
signal peptide | 10 |
secondary antibody | 10 |
polyacrylamide gel | 10 |
single immunization | 10 |
specific ifn | 10 |
cells per | 10 |
boosted group | 10 |
binding site | 10 |
heat shock | 10 |
metabolically labeled | 10 |
also inhibits | 10 |
viral membranes | 10 |
infected cell | 10 |
virus hemagglutinin | 10 |
gp ecto | 10 |
entry inhibitors | 10 |
boost vaccination | 10 |
virus titer | 10 |
baculovirus display | 10 |
prrsv envelope | 10 |
infected mice | 10 |
conjugated goat | 10 |
virus proteins | 10 |
eukaryotic ribosomes | 10 |
exchange vectors | 10 |
fluorescence microscope | 10 |
specific igg | 10 |
rna levels | 10 |
attenuated recombinant | 10 |
unpublished data | 10 |
suicide gene | 10 |
bd biosciences | 10 |
previously shown | 10 |
cell cultures | 10 |
structural components | 10 |
mice per | 10 |
based vaccines | 10 |
infectious particles | 10 |
translational control | 10 |
spanning domain | 10 |
genes encoding | 10 |
free medium | 10 |
thymidine kinase | 10 |
promoting ripa | 10 |
mrna synthesis | 10 |
virus infections | 10 |
er surface | 10 |
decreased polysome | 10 |
i glycopeptides | 10 |
export complex | 10 |
vp gene | 10 |
ge copies | 10 |
first position | 10 |
lentiviral vector | 10 |
tyrosine kinase | 10 |
widely used | 10 |
lumenal domain | 10 |
sars vaccine | 10 |
genome replication | 10 |
using anti | 10 |
newcastle disease | 10 |
free extracts | 10 |
culture plates | 10 |
mm nacl | 10 |
fd vsv | 10 |
vrp expressing | 10 |
ifit isg | 10 |
antigen expression | 9 |
infected hela | 9 |
heterologous animal | 9 |
irf mutant | 9 |
foreign antigen | 9 |
led us | 9 |
animal viruses | 9 |
late viral | 9 |
type ii | 9 |
serial sections | 9 |
public health | 9 |
stirred solution | 9 |
reverse transcription | 9 |
total protein | 9 |
tested whether | 9 |
throughput screening | 9 |
mouse hepatitis | 9 |
significantly stronger | 9 |
influenza virion | 9 |
authors declare | 9 |
mrna levels | 9 |
treated animals | 9 |
ripa branch | 9 |
infected ifit | 9 |
virus preparations | 9 |
stacking gel | 9 |
ethyl acetate | 9 |
plasma membranes | 9 |
vsv glycoprotein | 9 |
two independent | 9 |
broad spectrum | 9 |
viral diseases | 9 |
recombinant feline | 9 |
vsv recombinant | 9 |
serological assays | 9 |
adverse effects | 9 |
dendritic cells | 9 |
mers coronavirus | 9 |
apoptotic pathway | 9 |
surface area | 9 |
tetherin counteraction | 9 |
highest dilution | 9 |
surface display | 9 |
rna genome | 9 |
initiation factors | 9 |
vsv mrnas | 9 |
virus infected | 9 |
different cell | 9 |
restrictive temperature | 9 |
proteins found | 9 |
similar results | 9 |
cell tropism | 9 |
cell membranes | 9 |
significant reduction | 9 |
sequence analysis | 9 |
lymphocytic choriomeningitis | 9 |
budding profiles | 9 |
min chase | 9 |
units ml | 9 |
vsv proteins | 9 |
clinical signs | 9 |
low ph | 9 |
class ii | 9 |
random distribution | 9 |
biological activities | 9 |
serum dilution | 9 |
national institute | 9 |
viral fusion | 9 |
results showed | 9 |
small amount | 9 |
prototypic rvsv | 9 |
cell shut | 9 |
tripartite leader | 9 |
peptide pool | 9 |
high titer | 9 |
virus strain | 9 |
foreign gene | 9 |
leaky scanning | 9 |
reovirus mrnas | 9 |
virucidal activity | 9 |
life cycle | 9 |
total rna | 9 |
cellular protein | 9 |
enveloped rna | 9 |
neutralising antibodies | 9 |
rna replication | 9 |
cap methylation | 9 |
ebov challenge | 9 |
using recombinant | 9 |
hamster kidney | 9 |
translational regulation | 9 |
choriomeningitis virus | 9 |
competent vector | 9 |
evd survivor | 9 |
different viruses | 9 |
vectors transduced | 9 |
plasmid dna | 9 |
indirect immunofluorescence | 9 |
post challenge | 9 |
rvsv expressing | 9 |
commons license | 9 |
nuclear envelope | 9 |
mm sodium | 9 |
viral budding | 9 |
well plate | 9 |
driven entry | 9 |
leader rna | 9 |
recent studies | 9 |
initiator codon | 8 |
control cells | 8 |
expression system | 8 |
luciferase reporter | 8 |
high throughput | 8 |
intraperitoneally injected | 8 |
fusion proteins | 8 |
rna expression | 8 |
counting method | 8 |
different concentrations | 8 |
mdbk cells | 8 |
doxorubicin activates | 8 |
virus fusion | 8 |
class i | 8 |
dependent rna | 8 |
female balb | 8 |
type virus | 8 |
rbl cells | 8 |
human coronavirus | 8 |
gfp vlps | 8 |
mm hepes | 8 |
inhibitory effects | 8 |
aids vaccine | 8 |
gfp fluorescence | 8 |
mrna translation | 8 |
lassa fever | 8 |
cells untreated | 8 |
initiation site | 8 |
penicillin streptomycin | 8 |
expressing vsv | 8 |
old mice | 8 |
capsid protein | 8 |
peripheral sites | 8 |
essential medium | 8 |
mrna transcription | 8 |
particles per | 8 |
reverse transcriptase | 8 |
elevated temperature | 8 |
liquid nitrogen | 8 |
neutralizing activity | 8 |
plasmids encoding | 8 |
sds resistance | 8 |
induced cell | 8 |
proteolytic activation | 8 |
antigenic determinants | 8 |
proteins associated | 8 |
proteolytic digestion | 8 |
spike glycoproteins | 8 |
humoral immune | 8 |
ha spike | 8 |
given i | 8 |
surface glycoproteins | 8 |
cell signaling | 8 |
brain tissues | 8 |
human infection | 8 |
virus disease | 8 |
tetherin antagonist | 8 |
assay using | 8 |
coding region | 8 |
high concentrations | 8 |
dmem supplemented | 8 |
batfluav surface | 8 |
ifit protein | 8 |
spike glycoprotein | 8 |
expressing gml | 8 |
indiana serotype | 8 |
mem medium | 8 |
log pfu | 8 |
rvsv vaccine | 8 |
extracellular adp | 8 |
polyhedrosis virus | 8 |
vector system | 8 |
pseudotypes harboring | 8 |
influenza vaccine | 8 |
virucidal effect | 8 |
mouth disease | 8 |
virus neutralization | 8 |
cell receptor | 8 |
foreign glycoproteins | 8 |
recombinant vaccine | 8 |
horseradish peroxidase | 8 |
virus systems | 8 |
viral loads | 8 |
cells using | 8 |
growth factor | 8 |
neutralizing epitopes | 8 |
nhei restriction | 8 |
regulatory factor | 8 |
gfp cells | 8 |
golgi transport | 8 |
phosphate buffered | 8 |
cells treated | 8 |
pi treatment | 8 |
cells via | 8 |
ebov infection | 8 |
virus spread | 8 |
per infected | 8 |
inflammatory responses | 8 |
reduction neutralization | 8 |
brain cells | 8 |
binding medium | 8 |
rnp complexes | 8 |
herpes virus | 8 |
vsv spread | 8 |
single amino | 8 |
prok treatment | 8 |
vsv antibody | 8 |
using graphpad | 8 |
doxorubicin inhibited | 8 |
bee venom | 8 |
statistical analysis | 8 |
mrna expression | 8 |
zaire ebolavirus | 8 |
using lipofectamine | 8 |
specific antiviral | 8 |
test whether | 8 |
extensively washed | 8 |
growth kinetics | 8 |
alfalfa mosaic | 8 |
linked immunosorbent | 8 |
virus using | 8 |
reduced pressure | 8 |
consecutive sections | 8 |
glycosyl side | 8 |
viruses including | 8 |
vectored vaccine | 8 |
hiv protease | 8 |
crystal violet | 8 |
immunoprecipitated using | 8 |
virus genome | 8 |
specific proteins | 8 |
internal aug | 8 |
glycoprotein exchange | 8 |
competitive binding | 8 |
low dose | 8 |
personal communication | 8 |
infected insect | 8 |
electron microscope | 8 |
institutional animal | 8 |
may provide | 8 |
competent vsv | 8 |
per cell | 8 |
end point | 8 |
human coronaviruses | 8 |
vsvs expressing | 8 |
cell plasma | 8 |
intranasal inoculation | 8 |
viral vector | 8 |
hela cell | 8 |
acid residues | 8 |
encoded gfp | 8 |
parainfluenza virus | 8 |
vectored vaccines | 8 |
pyrvinium pamoate | 8 |
receptor binding | 8 |
tubular elements | 8 |
transmembrane serine | 8 |
thermofisher scientific | 8 |
weeks post | 8 |
challenge experiments | 8 |
doxorubicin promoted | 8 |
competent vesicular | 8 |
sphingomyelinase activity | 8 |
plaque forming | 7 |
virus gp | 7 |
virus adsorption | 7 |
previous reports | 7 |
efficient translation | 7 |
rlr stimulation | 7 |
cycle vectors | 7 |
total volume | 7 |
bone marrow | 7 |
mean sd | 7 |
protein bands | 7 |
yersinia pestis | 7 |
ge healthcare | 7 |
polyacrylamide gels | 7 |
innate immunity | 7 |
within days | 7 |
chikungunya virus | 7 |
mammalian cell | 7 |
effective aids | 7 |
log tcid | 7 |
virus attachment | 7 |
equal volume | 7 |
based vectors | 7 |
uranyl acetate | 7 |
ifit proteins | 7 |
abl tyrosine | 7 |
membrane components | 7 |
pancreatic acinar | 7 |
inhibit virus | 7 |
restricted mutant | 7 |
protein inhibits | 7 |
ha na | 7 |
cytoplasmic abundance | 7 |
cellular receptor | 7 |
cellular membrane | 7 |
infection without | 7 |
virus pseudotypes | 7 |
virus replicon | 7 |
er export | 7 |
ifn response | 7 |
lentiviral pseudotyped | 7 |
second bud | 7 |
use committee | 7 |
immune cell | 7 |
translational efficiency | 7 |
wide range | 7 |
hours post | 7 |
sodium dodecyl | 7 |
bat cells | 7 |
vaccine approach | 7 |
dna vaccines | 7 |
growth medium | 7 |
clinical studies | 7 |
biologically active | 7 |
data demonstrated | 7 |
previous work | 7 |
ribosome binding | 7 |
virus budding | 7 |
avian leukosis | 7 |
virus vector | 7 |
resistant oligomers | 7 |
kda protein | 7 |
mouse anti | 7 |
vector based | 7 |
egfp expression | 7 |
purified virus | 7 |
buffer containing | 7 |
yellow fever | 7 |
ch cl | 7 |
nrk cells | 7 |
biological activity | 7 |
log increase | 7 |
transgene expression | 7 |
vsv titers | 7 |
intranasal infection | 7 |
large oligomer | 7 |
planar projection | 7 |
clinical trial | 7 |
vitro models | 7 |
cancer cells | 7 |
infected mouse | 7 |
cytopathic effects | 7 |
expression vectors | 7 |
host shut | 7 |
vsv neutralizing | 7 |
cellular genes | 7 |
viral nucleocapsid | 7 |
virus structural | 7 |
three different | 7 |
mutant lxxxl | 7 |
purified virions | 7 |
codon usage | 7 |
fresh culture | 7 |
doxorubicin also | 7 |
cells challenged | 7 |
recombinant human | 7 |
viral polypeptides | 7 |
cell type | 7 |
day post | 7 |
natural host | 7 |
generated using | 7 |
hepatocellular carcinoma | 7 |
export sites | 7 |
vsv infected | 7 |
mediated cell | 7 |
treated samples | 7 |
national institutes | 7 |
lg ml | 7 |
tumor growth | 7 |
tcid ml | 7 |
endosomal membranes | 7 |
spike rbd | 7 |
studies will | 7 |
encephalomyocarditis virus | 7 |
major structural | 7 |
golgi region | 7 |
dna viruses | 7 |
smaller polysomes | 7 |
antiviral effects | 7 |
surface density | 7 |
humoral response | 7 |
protein may | 7 |
host factors | 7 |
stimulated genes | 7 |
may reflect | 7 |
provides complete | 7 |
viral pathogenesis | 7 |
lipid composition | 7 |
kinase gene | 7 |
less efficiently | 7 |
stop codon | 7 |
inhibits host | 7 |
pancreatic cancer | 7 |
cycle vsv | 7 |
major enu | 7 |
sensitive mutants | 7 |
firefly luciferase | 7 |
recombinant vaccinia | 7 |
proteolytic processing | 7 |
schwannoma cells | 7 |
expressing glycoproteins | 7 |
virus vaccines | 7 |
measured using | 7 |
challenge virus | 7 |
kcal mol | 7 |
protein composition | 7 |
adenovirus type | 7 |
spectral counts | 7 |
highly susceptible | 7 |
viral infectivity | 7 |
induced protein | 7 |
plaque assays | 7 |
different vsvs | 7 |
vivo studies | 7 |
ha protein | 7 |
normal brain | 7 |
vsv indiana | 7 |
examine whether | 7 |
neutralizing titers | 7 |
nonsegmented negative | 7 |
prism software | 7 |
facs analysis | 7 |
right panel | 7 |
ht cells | 7 |
virus membrane | 7 |
knockout mice | 7 |
second aug | 7 |
small molecule | 7 |
virus recombinant | 7 |
major surface | 7 |
early mrnas | 7 |
purified using | 7 |
using hexane | 7 |
soluble expression | 7 |
binding assay | 7 |
persistent infection | 7 |
united states | 7 |
marburg virus | 7 |
permissive temperature | 7 |
neuraminidase activity | 7 |
aqueous solution | 7 |
crystal structure | 7 |
olfactory bulbs | 7 |
external surface | 7 |
poliovirus mrna | 7 |
african green | 7 |
proteomic analysis | 7 |
animal experiments | 7 |
scientificreports www | 7 |
disease control | 7 |
inhibit viral | 7 |
fluorescence microscopy | 7 |
best studied | 7 |
results demonstrated | 7 |
negative strand | 7 |
enu start | 7 |
gml oligomer | 7 |
mice developed | 7 |
retroviral vector | 7 |
human pathogens | 7 |
purified recombinant | 7 |
pcr amplification | 6 |
internal proteins | 6 |
infection results | 6 |
log scale | 6 |
green monkey | 6 |
elicit robust | 6 |
mice showed | 6 |
gives rise | 6 |
minimum essential | 6 |
expression systems | 6 |
californica nuclear | 6 |
cap equivalent | 6 |
host rna | 6 |
whether vsv | 6 |
microplate reader | 6 |
early region | 6 |
gfp infected | 6 |
ebov vaccine | 6 |
ace interaction | 6 |
body temperature | 6 |
essential role | 6 |
wild type | 6 |
induced ifit | 6 |
transmission electron | 6 |
vsv pseudotype | 6 |
may occur | 6 |
vaccine production | 6 |
chain reaction | 6 |
without affecting | 6 |
lethal ebola | 6 |
data indicate | 6 |
incubated overnight | 6 |
throughput screen | 6 |
two methods | 6 |
medium supplemented | 6 |
intramuscular injection | 6 |
vivo gene | 6 |
containing viruses | 6 |
i ifns | 6 |
mediated tetherin | 6 |
high degree | 6 |
molecular probes | 6 |
entry requires | 6 |
frog virus | 6 |
independent replicates | 6 |
cellular membranes | 6 |
wheat germ | 6 |
attenuation strategies | 6 |
expressing ebovgp | 6 |
fresh medium | 6 |
competent construct | 6 |
antiviral properties | 6 |
different regions | 6 |
cap structure | 6 |
acid sequences | 6 |
distilled water | 6 |
intranasal vaccination | 6 |
bat influenza | 6 |
shock protein | 6 |
neutralization antibodies | 6 |
baby hamster | 6 |
neutralization antibody | 6 |
foreign proteins | 6 |
baculovirus expression | 6 |
wsn strain | 6 |
dimensional organization | 6 |
animal studies | 6 |
gene products | 6 |
either vsv | 6 |
associated virus | 6 |
mice expressing | 6 |
protective immunity | 6 |
innate antiviral | 6 |
expressing hafl | 6 |
red blood | 6 |
entry assay | 6 |
internal initiation | 6 |
ebola vaccine | 6 |
codon occurs | 6 |
cem gfp | 6 |
average number | 6 |
high generation | 6 |
colorless oil | 6 |
glass coverslips | 6 |
including vsv | 6 |
igg titers | 6 |
avian sarcoma | 6 |
standard deviation | 6 |
poliovirus rna | 6 |
infection experiments | 6 |
likely due | 6 |
oncolytic vesicular | 6 |
virus encephalitis | 6 |
hiv env | 6 |
inhibits viral | 6 |
competing interests | 6 |
designated pvsv | 6 |
attenuated vsvs | 6 |
mutant virus | 6 |
life technologies | 6 |
rvsv hiv | 6 |
virus input | 6 |
cd expression | 6 |
directly inhibit | 6 |
virus ankara | 6 |
enriched membrane | 6 |
may contribute | 6 |
cells plated | 6 |
cytoplasmic fraction | 6 |
sequence homology | 6 |
intranasally infected | 6 |
vaccinated group | 6 |
particle release | 6 |
standard deviations | 6 |
glycoprotein species | 6 |
ml domain | 6 |
also used | 6 |
virus pseudotype | 6 |
fold increase | 6 |
previously published | 6 |
mass spectrometry | 6 |
inhibits vsv | 6 |
allantoic fluid | 6 |
table iii | 6 |
nuclear polyhedrosis | 6 |
units per | 6 |
single cycle | 6 |
vectors showed | 6 |
potent anti | 6 |
per ixm | 6 |
viruses expressing | 6 |
significantly increased | 6 |
primary structure | 6 |
gp mab | 6 |
virus grown | 6 |
vitro antiviral | 6 |
human primates | 6 |
cleavage sites | 6 |
influenza viral | 6 |
ni affinity | 6 |
virus protein | 6 |
chandipura virus | 6 |
one mrna | 6 |
prrsv proteins | 6 |
assays using | 6 |
lethal ebov | 6 |
completely inhibited | 6 |
ace receptor | 6 |
shutoff mechanism | 6 |
based pseudotyped | 6 |
polymerase chain | 6 |
review see | 6 |
molecular weights | 6 |
acid sequence | 6 |
surface expression | 6 |
functional receptor | 6 |
co atmosphere | 6 |
calculated using | 6 |
complete medium | 6 |
open access | 6 |
gene ontology | 6 |
stem cell | 6 |
peer review | 6 |
intracranial inoculation | 6 |
hemagglutinating activity | 6 |
polysome fractions | 6 |
efficient transduction | 6 |
modified vaccinia | 6 |
dose vaccination | 6 |
viral mutant | 6 |
inhibit translation | 6 |
trypan blue | 6 |
provide evidence | 6 |
sulfur atom | 6 |
virus stock | 6 |
plasma samples | 6 |
adenovirus early | 6 |
family members | 6 |
either one | 6 |
directed expression | 6 |
antiviral drug | 6 |
nonstructural proteins | 6 |
values obtained | 6 |
sample types | 6 |
current status | 6 |
one might | 6 |
major groups | 6 |
candidate vaccine | 6 |
cov neutralization | 6 |
translational capacity | 6 |
mumps virus | 6 |
ebovgp gene | 6 |
studies revealed | 6 |
mediated entry | 6 |
complete nucleotide | 6 |
examined whether | 6 |
virus species | 6 |
pet cats | 6 |
per se | 6 |
baculovirus surface | 6 |
ml recombinant | 6 |
membrane glycoproteins | 6 |
distantly connected | 6 |
fold lower | 6 |
transmembrane domains | 6 |
tests using | 6 |
cd low | 6 |
protein cytoplasmic | 6 |
ii transmembrane | 6 |
infect cells | 6 |
viral titer | 6 |
much lower | 6 |
factor eif | 6 |
progenitor cells | 6 |
purified mab | 6 |
intranasal vsv | 6 |
restriction factor | 6 |
six times | 6 |
results obtained | 6 |
spike proteins | 6 |
kinase inhibitor | 6 |
nv model | 6 |
metabolically radiolabeled | 6 |
moloney murine | 6 |
cell receptors | 6 |
pg ml | 6 |
total er | 6 |
peptide pools | 6 |
mouse serum | 6 |
flag epitope | 6 |
polypeptide chains | 6 |
molecular mass | 6 |
closely related | 6 |
supplementary table | 6 |
reporter genes | 6 |
plaque reduction | 6 |
also found | 6 |
see materials | 6 |
antibody directed | 6 |
oncolytic virus | 6 |
results show | 6 |
active site | 6 |
tris ph | 6 |
interferon omega | 6 |
statistical analyses | 6 |
specific neutralizing | 6 |
overall decline | 6 |
nm gold | 6 |
treatment inhibited | 6 |
ms ms | 6 |
kidney epithelial | 6 |
gammaretroviral vectors | 6 |
like receptor | 6 |
following challenge | 6 |
hal proteins | 6 |
associated coronavirus | 6 |
ammonium chloride | 6 |
immunosorbent assay | 6 |
small molecules | 6 |
tobacco mosaic | 6 |
experimental animal | 6 |
deficient mice | 6 |
world health | 6 |
entry driven | 6 |
san diego | 6 |
embryonic fibroblasts | 6 |
additional transcription | 6 |
based ebola | 6 |
findings suggest | 6 |
ribonucleic acid | 6 |
nasal epithelial | 6 |
vaccine candidate | 6 |
mean surface | 6 |
enveloped virus | 6 |
type mice | 6 |
cleavage site | 6 |
extracellular domain | 6 |
pseudotype entry | 6 |
blot analysis | 6 |
beta interferon | 6 |
jak stat | 5 |
different vsv | 5 |
iptg concentration | 5 |
strong humoral | 5 |
purinergic receptors | 5 |
transduced tumor | 5 |
cell proteins | 5 |
olot strain | 5 |
signal pathway | 5 |
inhibits virus | 5 |
mem i | 5 |
gene translocations | 5 |
serum albumin | 5 |
high virus | 5 |
following vsv | 5 |
two groups | 5 |
replicon particles | 5 |
viral genomes | 5 |
many viruses | 5 |
glycoprotein gene | 5 |
neutralization titers | 5 |
prrsv antigens | 5 |
investigated whether | 5 |
inhibit vsv | 5 |
herpes viruses | 5 |
animal welfare | 5 |
virion samples | 5 |
partial inhibition | 5 |
feline immunodeficiency | 5 |
response curves | 5 |
free systems | 5 |
lateral diffusion | 5 |
recombinant expressing | 5 |
study showed | 5 |
immunofluorescence assay | 5 |
acinar cells | 5 |
genome organization | 5 |
restriction site | 5 |
major viral | 5 |
ml streptomycin | 5 |
continuous cell | 5 |
respiratory tract | 5 |
vsv leader | 5 |
signal sequence | 5 |
health organization | 5 |
cell gene | 5 |
tested cells | 5 |
converting enzyme | 5 |
crispr cas | 5 |
equine encephalitis | 5 |
assay kit | 5 |
sfcs splenocytes | 5 |
major capsid | 5 |
highly significant | 5 |
phosphorylation sites | 5 |
lassa virus | 5 |
hiv gag | 5 |
oligosaccharide side | 5 |
proven protease | 5 |
accession number | 5 |
imaging system | 5 |
vsv replicons | 5 |
antiviral genes | 5 |
well tolerated | 5 |
rhabdoviridae family | 5 |
two additional | 5 |
pandemic influenza | 5 |
termination codon | 5 |
downstream site | 5 |
either immediately | 5 |
graphpad software | 5 |
virus pathogenesis | 5 |
phenotypic mixing | 5 |
cytokine responses | 5 |
randomly chosen | 5 |
new subtypes | 5 |
viral suspensions | 5 |
human cd | 5 |
virus assays | 5 |
feline infectious | 5 |
zika virus | 5 |
study endpoint | 5 |
aug triplets | 5 |
carbohydrate composition | 5 |
liver diseases | 5 |
background level | 5 |
integral membrane | 5 |
ti rotor | 5 |
soluble forms | 5 |
prrsv infection | 5 |
prokaryotic soluble | 5 |
covalently linked | 5 |
simian immunodeficiency | 5 |
tetherin antagonists | 5 |
using previously | 5 |
cells ml | 5 |
camp epac | 5 |
infectious virion | 5 |
nude rats | 5 |
years ago | 5 |
side chain | 5 |
viral envelopes | 5 |
viruses infecting | 5 |
several viruses | 5 |
study demonstrated | 5 |
cellular entry | 5 |
genomic cdna | 5 |
two new | 5 |
interfering rna | 5 |
wnv infection | 5 |
mouse survival | 5 |
ebovgp vector | 5 |
mcias using | 5 |
purified vsv | 5 |
several studies | 5 |
globin mrna | 5 |
studies demonstrate | 5 |
pseudotype particles | 5 |
pikfyve kinase | 5 |
entry efficiency | 5 |
optimal induction | 5 |
eukaryotic initiation | 5 |
inhibit host | 5 |
evaluated using | 5 |
will likely | 5 |
vai rna | 5 |
animals developed | 5 |
coli strains | 5 |
vaccine approaches | 5 |
tag ni | 5 |
induced inhibition | 5 |
protective humoral | 5 |
cchfv challenge | 5 |
copi coats | 5 |
protein transport | 5 |
virusinfected cells | 5 |
optimal antiviral | 5 |
cause severe | 5 |
dna replication | 5 |
viral systems | 5 |
binding domains | 5 |
scanning mechanism | 5 |
escherichia coli | 5 |
concentric shells | 5 |
hind limb | 5 |
antibody positive | 5 |
receptor molecule | 5 |
secretory pathway | 5 |
coronavirus disease | 5 |
cell extracts | 5 |
see section | 5 |
neutralization epitopes | 5 |
fold higher | 5 |
like receptors | 5 |
intracellular trafficking | 5 |
vaccinated pigs | 5 |
observations suggest | 5 |
among different | 5 |
several approaches | 5 |
protects nonhuman | 5 |
safety studies | 5 |
uitro translation | 5 |
hiv type | 5 |
animal species | 5 |
plaque formation | 5 |
genomic dna | 5 |
immunodiffusion protocol | 5 |
different recombinant | 5 |
induction conditions | 5 |
cholesterol transporter | 5 |
empty plasmid | 5 |
virus isolates | 5 |
wide variety | 5 |
competent cells | 5 |
transfected bhk | 5 |
foreign protein | 5 |
congo haemorrhagic | 5 |
dmem medium | 5 |
groups compared | 5 |
hcg antibody | 5 |
protein complex | 5 |
derived buds | 5 |
reticulocyte lysate | 5 |
antiviral defense | 5 |
infectious peritonitis | 5 |
vsv platform | 5 |
er bud | 5 |
plasmid pvsv | 5 |
sugar ring | 5 |
ifn system | 5 |
may result | 5 |
viral glycoprotein | 5 |
recombinant virus | 5 |
bearing pseudotypes | 5 |
model system | 5 |
monkey kidney | 5 |
experimental vaccines | 5 |
ripa contributes | 5 |
two distinct | 5 |
potential antiviral | 5 |
serum antibodies | 5 |
viral neuraminidase | 5 |
side chains | 5 |
intranasally vsv | 5 |
results led | 5 |
human population | 5 |
defective interfering | 5 |
drug screening | 5 |
plasmid encoding | 5 |
elispot responses | 5 |
gene product | 5 |
control serum | 5 |
regional foci | 5 |
serial dilution | 5 |
antiviral function | 5 |
cleavage products | 5 |
rat glioma | 5 |
mice infected | 5 |
cytoplasmic mrna | 5 |
encoding feifn | 5 |
many different | 5 |
effective therapeutic | 5 |
recognition receptors | 5 |
radiolabeled vsv | 5 |
vero cell | 5 |
days pi | 5 |
also induced | 5 |
using intercat | 5 |
pc cells | 5 |
kinase inhibitors | 5 |
ng hiv | 5 |
like cells | 5 |
biochemical studies | 5 |
imaged using | 5 |
rhesus macaques | 5 |
human clinical | 5 |
data presented | 5 |
rvsv ebov | 5 |
inhibits infection | 5 |
baculovirus displaying | 5 |
even though | 5 |
parental vsv | 5 |
clinical evaluation | 5 |
intracellular compartments | 5 |
reg cells | 5 |
pseudotyped baculovirus | 5 |
untreated cells | 5 |
final volume | 5 |
adenovirus mrnas | 5 |
oncolytic vsv | 5 |
capped mrnas | 5 |
research institute | 5 |
hybridoma supernatant | 5 |
specific activity | 5 |
immune serum | 5 |
therapeutic agents | 5 |
wt vol | 5 |
sino biological | 5 |
evd survivors | 5 |
phylogenetic tree | 5 |
molecule inhibitors | 5 |
tail length | 5 |
cd cells | 5 |
neutralising activity | 5 |
ripa activators | 5 |
novel antiviral | 5 |
brain tumors | 5 |
using two | 5 |
small mammals | 5 |
highly effective | 5 |
vectors will | 5 |
nhp nv | 5 |
free dmem | 5 |
ncov usa | 5 |
uninfected rn | 5 |
acid substitutions | 5 |
apilimod blocks | 5 |
ma cells | 5 |
infection conferred | 5 |
reduced tetherin | 5 |
tissue tropism | 5 |
within vtcs | 5 |
cells date | 5 |
complementary sequences | 5 |
fruit bat | 5 |
normal shutoff | 5 |
binding sites | 5 |
competent vaccine | 5 |
dodecyl sulfate | 5 |
using pseudotyped | 5 |
plasmid system | 5 |
homologous animal | 5 |
activate ripa | 5 |
gtp restricted | 5 |
structural protein | 5 |
bars represent | 5 |
well culture | 5 |
ifn action | 5 |
per ml | 5 |
virus growth | 5 |
clinical development | 5 |
vsv particle | 5 |
tissue sections | 5 |
favorable context | 5 |
disease following | 5 |
atcc ccl | 5 |
deep sequencing | 5 |
volume ratio | 5 |
vsv adsorption | 5 |
vesicle budding | 5 |
average rlu | 5 |
activate irf | 5 |
stat pathway | 5 |
virus pseudotyped | 5 |
vsv expressing | 5 |
alkaline phosphatase | 5 |
affinity column | 5 |
conjugated secondary | 5 |
potent protective | 5 |
structural component | 5 |
cytotoxic effects | 5 |
mice exhibited | 5 |
functional characterization | 5 |
derived vesicles | 5 |
ml penicillin | 5 |
previously demonstrated | 5 |
prompted us | 5 |
phase i | 5 |
serine proteases | 5 |
hypertonic stress | 5 |
simian virus | 5 |
clinically proven | 5 |
natural reservoir | 5 |
vsv activity | 5 |
quantified using | 5 |
cauliflower mosaic | 5 |
macromolecular synthesis | 5 |
fourth transcription | 5 |
induced apoptosis | 5 |
glioma model | 5 |
way anova | 5 |
virion surface | 5 |
mouse pems | 5 |
cells well | 5 |
pseudotypes using | 5 |
invasive areas | 5 |
rbd protein | 5 |
neuraminic acid | 5 |
andes virus | 5 |
highly efficient | 5 |
proteins encoded | 5 |
rapid protection | 5 |
associated mrna | 5 |
pathogens including | 5 |
optimized vaccine | 5 |
washed six | 5 |
aug triplet | 5 |
studies using | 5 |
cd ifn | 5 |
human monoclonal | 5 |
cell growth | 5 |
expression using | 5 |
eight hours | 5 |
neutralized vsv | 5 |
transiently transfected | 5 |
protease treatment | 5 |
novel virus | 5 |
observed using | 5 |
hong kong | 5 |
rat schwannoma | 5 |
transcription stop | 5 |
proteins expressed | 5 |
incorporated efficiently | 5 |
peptide cleavage | 5 |
virus may | 5 |
inhibit acid | 5 |
performed mcias | 5 |
signaling competent | 5 |
plos one | 5 |
encoded proteins | 5 |
glycoproteins expressed | 5 |
naturally occurring | 5 |
new england | 5 |
membrane structure | 5 |
marburg viruses | 5 |
diarrhea virus | 5 |
heterologous challenge | 5 |
cell duplication | 5 |
fluorescent vlps | 5 |
sw ti | 5 |
approximately kda | 5 |
polysome fraction | 5 |
subcellular localization | 5 |
endosomal ph | 5 |
input virus | 5 |
strong immune | 5 |
infectious centres | 5 |
limb paralysis | 5 |
liquid chromatography | 5 |
induction time | 5 |
golgi compartments | 5 |
transfection medium | 5 |
polyclonal rabbit | 5 |
i interferons | 5 |
viral disease | 5 |
commons attribution | 5 |
encode proteins | 5 |
adenovirus va | 5 |
natural infection | 5 |
laboratory animal | 5 |
transitional region | 5 |
transcription gradient | 5 |
infectious units | 5 |
ifit genes | 5 |
cellular infection | 5 |
internal surface | 5 |
control vsv | 5 |
sequence reads | 5 |
gene induction | 5 |
malignant glioma | 5 |
expressing egfp | 5 |
mediated neutralization | 5 |
competent rvsv | 5 |
induced irf | 5 |
prrsv gp | 5 |
mediated activation | 5 |
experimental conditions | 5 |
mouse monoclonal | 5 |
membrane receptors | 4 |
certain bat | 4 |
thigh muscle | 4 |
nuclear margin | 4 |
showed similar | 4 |
may interact | 4 |
ifn receptor | 4 |
polymerase protein | 4 |
reduced vsv | 4 |
inoculated intranasally | 4 |
one based | 4 |
severe respiratory | 4 |
modified eagle | 4 |
irf transcriptional | 4 |
arabian peninsula | 4 |
fixation conditions | 4 |
zaire ebola | 4 |
protein exchange | 4 |
might mediate | 4 |
rabbit papillomavirus | 4 |
vector laboratories | 4 |
uracil nucleoside | 4 |
venezuelan equine | 4 |
decreasing amounts | 4 |
virus binding | 4 |
human transmission | 4 |
asked whether | 4 |
highly invasive | 4 |
potentially zoonotic | 4 |
coomassie staining | 4 |
cell cytoplasm | 4 |
virus life | 4 |
protease tmprss | 4 |
sodium ions | 4 |
new world | 4 |
following lethal | 4 |
elevated temperatures | 4 |
human viruses | 4 |
polymerase ii | 4 |
vsv vaccine | 4 |
effect inhibition | 4 |
transmembrane region | 4 |
cell volume | 4 |
apoptotic cells | 4 |
coronavirus receptor | 4 |
imatinib inhibits | 4 |
surface antigen | 4 |
therapeutic effect | 4 |
tmprss cells | 4 |
studies reported | 4 |
neutral ceramidase | 4 |
cell biol | 4 |
slightly lower | 4 |
virus maturation | 4 |
small interfering | 4 |
robust cd | 4 |
protective potential | 4 |
igg response | 4 |
monitored daily | 4 |
glycoprotein precursor | 4 |
santa cruz | 4 |
humanely euthanized | 4 |
nahco aqueous | 4 |
human influenza | 4 |
conducted using | 4 |
antibodies specific | 4 |
interferon regulatory | 4 |
mammalian expression | 4 |
docking scores | 4 |
nonstructural protein | 4 |
cytotoxic concentration | 4 |
doubly infected | 4 |
th fractions | 4 |
puc vector | 4 |
detection system | 4 |
blue exclusion | 4 |
antagonize tetherin | 4 |
black beetle | 4 |
sanger sequencing | 4 |
findings indicate | 4 |
nucleotide sequences | 4 |
vsv replicates | 4 |
virus titre | 4 |
expressing either | 4 |
complement control | 4 |
genbank accession | 4 |
sand flies | 4 |
porcine tetherin | 4 |
protein interactions | 4 |
antibody neutralization | 4 |
budding sites | 4 |
structural polypeptides | 4 |
nitrocellulose membranes | 4 |
cd apc | 4 |
thank also | 4 |
convalescent sera | 4 |
using flowjo | 4 |
comparable growth | 4 |
vaccine virus | 4 |
virus sv | 4 |
infectious viral | 4 |
significantly reduced | 4 |
one type | 4 |
also activate | 4 |
vitro studies | 4 |
two glycoproteins | 4 |
markers nestin | 4 |
empty expression | 4 |
associated influenza | 4 |
prepared using | 4 |
embryonated chicken | 4 |
tumor areas | 4 |
new york | 4 |
increasing amounts | 4 |
dead cells | 4 |
positive tumor | 4 |
vaccines protect | 4 |
singlestranded rna | 4 |
high susceptibility | 4 |
exhibited potent | 4 |
gradient sedimentation | 4 |
dependent protein | 4 |
mouse bmdms | 4 |
hsv type | 4 |
signaling pathways | 4 |
hybridoma cell | 4 |
translational modifications | 4 |
encoded vsv | 4 |
mean cell | 4 |
activate hal | 4 |
novel vesicular | 4 |
study day | 4 |
cellular gene | 4 |
virion formation | 4 |
strand viruses | 4 |
hybridoma antibodies | 4 |
vesicular carriers | 4 |
treated groups | 4 |
complete sequence | 4 |
will need | 4 |
culture models | 4 |
cell functions | 4 |
biological functions | 4 |
initiating cells | 4 |
detect mers | 4 |
dna damage | 4 |
therapeutic efficacy | 4 |
ts vsv | 4 |
mice inoculated | 4 |
vector attenuation | 4 |
antibody specific | 4 |
major protein | 4 |
ascites tumor | 4 |
studies described | 4 |
mice succumbed | 4 |
proteins required | 4 |
hours prior | 4 |
performed according | 4 |
protective effect | 4 |
blocks infection | 4 |
distributed throughout | 4 |
forming assay | 4 |
cell biology | 4 |
start signal | 4 |
hemagglutinin provides | 4 |
triplicate wells | 4 |
cell targeting | 4 |
blood cells | 4 |
carboxyl terminus | 4 |
native pr | 4 |
slow shaking | 4 |
vsv pathogenesis | 4 |
electrophoretic mobility | 4 |
containing mm | 4 |
capsid proteins | 4 |
colorless sticky | 4 |
histopathological examination | 4 |
highly enriched | 4 |
alpha beta | 4 |
structural glycoproteins | 4 |
differential inhibition | 4 |
thank dr | 4 |
three groups | 4 |
large numbers | 4 |
cell supernatant | 4 |
different amounts | 4 |
host species | 4 |
forward primer | 4 |
control animals | 4 |
leukaemia virus | 4 |
days without | 4 |
fluc activity | 4 |
glycoproteins may | 4 |
stable expression | 4 |
experimental vaccine | 4 |
hl nl | 4 |
gradient centrifugation | 4 |
vsv mrna | 4 |
luciferase assay | 4 |
starting dilution | 4 |
goose erythrocytes | 4 |
cellular tropism | 4 |
temperature overnight | 4 |
genetic information | 4 |
kos strain | 4 |
free translation | 4 |
ideal balance | 4 |
mature virus | 4 |
distinct mechanisms | 4 |
group also | 4 |
therapeutic options | 4 |
replication deficient | 4 |
eagle medium | 4 |
adherent cells | 4 |
molecular mechanisms | 4 |
times higher | 4 |
coronavirus associated | 4 |
data show | 4 |
influenza vaccines | 4 |
purinergic signaling | 4 |
coxsackie virus | 4 |
sequence encoding | 4 |
significantly inhibited | 4 |
seven distinct | 4 |
study provides | 4 |
vsv pseudotyped | 4 |
possible explanation | 4 |
alternative method | 4 |
field isolates | 4 |
histocompatibility complex | 4 |
buds detected | 4 |
strong neutralizing | 4 |
small fraction | 4 |
tg ml | 4 |
vectors based | 4 |
model using | 4 |
type virions | 4 |
intranasal route | 4 |
higher expression | 4 |
pilot studies | 4 |
using monoclonal | 4 |
using primers | 4 |
human cell | 4 |
adaptive immune | 4 |
family rhabdoviridae | 4 |
one another | 4 |
protein provides | 4 |
infecting bhk | 4 |
viral rnp | 4 |
cell supernatants | 4 |
limiting membrane | 4 |
control pnhs | 4 |
gene expressing | 4 |
cytoplasmic membranes | 4 |
combination therapy | 4 |
future studies | 4 |
infectious dose | 4 |
control mice | 4 |
dipeptidyl peptidase | 4 |
antigen presentation | 4 |
immunized mice | 4 |
cytosine nucleoside | 4 |
virus stocks | 4 |
immunofluorescence microscopy | 4 |
restricts viral | 4 |
least two | 4 |
also obtained | 4 |
phlebotomine sandflies | 4 |
detectable antibody | 4 |
remain polysome | 4 |
enhanced green | 4 |
positive way | 4 |
two genes | 4 |
whole virion | 4 |
either wt | 4 |
vsv protein | 4 |
resulting plasmid | 4 |
mediate entry | 4 |
activate batfluav | 4 |
cmv promoter | 4 |
hafl vaccines | 4 |
treated vsv | 4 |
deleterious effects | 4 |
host interactions | 4 |
approximately nm | 4 |
technical replicates | 4 |
transmembrane protein | 4 |
novel arthropod | 4 |
foreign antigens | 4 |
vsv genes | 4 |
murine retroviruses | 4 |
brome mosaic | 4 |
receptor cd | 4 |
table ii | 4 |
confocal microscopy | 4 |
promising vaccine | 4 |
blocked formation | 4 |
brain tumor | 4 |
clinical applications | 4 |
ethanol administration | 4 |
neuraminidase activities | 4 |
zebov infection | 4 |
polymerase complex | 4 |
ten days | 4 |
trypsin inhibitor | 4 |
novel viruses | 4 |
membrane glycoprotein | 4 |
interferon system | 4 |
hep cells | 4 |
may represent | 4 |
vsv neutralisation | 4 |
interferon genes | 4 |
virus thymidine | 4 |
dilution factor | 4 |
mouse embryonic | 4 |
organic layer | 4 |
vaccine efficacy | 4 |
activates ripa | 4 |
assay based | 4 |
gp fusion | 4 |
ns proteins | 4 |
ifn production | 4 |
vaccine viruses | 4 |
temperature sensitive | 4 |
solubilized either | 4 |
truncated form | 4 |
membrane domains | 4 |
borne encephalitis | 4 |
virus induced | 4 |
budded baculovirus | 4 |
vaccine platform | 4 |
using vesicular | 4 |
pol gene | 4 |
efficient recovery | 4 |
translation efficiency | 4 |
cycle replication | 4 |
molecular cloning | 4 |
insect virus | 4 |
promoting compounds | 4 |
codon optimized | 4 |
luis enjuanes | 4 |
using pseudotype | 4 |
activating compounds | 4 |
max nm | 4 |
human anti | 4 |
rvsv genome | 4 |
mitsunobu reaction | 4 |
considered significant | 4 |
camp plays | 4 |
respiratory disease | 4 |
newly generated | 4 |
survival rate | 4 |
glycoprotein expression | 4 |
ifn antiviral | 4 |
several different | 4 |
mediated gene | 4 |
intracellular migration | 4 |
conferred protection | 4 |
tandem mass | 4 |
cell leukemia | 4 |
vsb chain | 4 |
serum sample | 4 |
line expressing | 4 |
tier ii | 4 |
based expression | 4 |
igg responses | 4 |
replication step | 4 |
biological properties | 4 |
restore translation | 4 |
egfp complemented | 4 |
lethal homologous | 4 |
early shutoff | 4 |
induced caspase | 4 |
different attenuated | 4 |
cells compared | 4 |
markedly reduced | 4 |
hcl ph | 4 |
secreted ebovgp | 4 |
recurrent tumors | 4 |
dividing cells | 4 |
gene sequences | 4 |
cell markers | 4 |
type env | 4 |
times post | 4 |
minimal conserved | 4 |
latent state | 4 |
cells used | 4 |
nih aids | 4 |
induced release | 4 |
potent inhibition | 4 |
caudal thigh | 4 |
type gd | 4 |
dropwise added | 4 |
analysis using | 4 |
lytic infection | 4 |
synthesized proteins | 4 |
form hetero | 4 |
used previously | 4 |
lentiviral pseudotypes | 4 |
expression level | 4 |
efficient gene | 4 |
farther downstream | 4 |
sample buffer | 4 |
entry mediated | 4 |
highly immunogenic | 4 |
hypertonic conditions | 4 |
viral components | 4 |
neurotropic virus | 4 |
scanning model | 4 |
trypsin digestion | 4 |
promotes stable | 4 |
related viruses | 4 |
transfected hela | 4 |
three days | 4 |
budded virions | 4 |
protein incorporation | 4 |
nucleic acid | 4 |
described procedures | 4 |
growth curves | 4 |
chicken embryo | 4 |
protein levels | 4 |
gml oligomerization | 4 |
infected patients | 4 |
hpai viruses | 4 |
transgene delivery | 4 |
protected mice | 4 |
brain cancer | 4 |
class iii | 4 |
hal cleavage | 4 |
protein gene | 4 |
influenza strains | 4 |
emerging human | 4 |
ha hal | 4 |
determined whether | 4 |
intracellular membranes | 4 |
significant survival | 4 |
virus types | 4 |
target genes | 4 |
antigenic changes | 4 |
vectors containing | 4 |
borne viruses | 4 |
suboptimal context | 4 |
reduced polysome | 4 |
viral activity | 4 |
competent virus | 4 |
using baculovirus | 4 |
intraperitoneally treated | 4 |
affect viral | 4 |
cov receptor | 4 |
ic values | 4 |
high affinity | 4 |
treated group | 4 |
fatality rates | 4 |
culture dishes | 4 |
ebov vector | 4 |
mediated endocytosis | 4 |
endosomal proteolysis | 4 |
indicated time | 4 |
viruses possess | 4 |
gfp co | 4 |
vaccines expressing | 4 |
specific serum | 4 |
bearing hal | 4 |
fold greater | 4 |
invaded virus | 4 |
four groups | 4 |
connected er | 4 |
baculovirus particles | 4 |
chicken eggs | 4 |
robust increase | 4 |
significantly lower | 4 |
specific pathogen | 4 |
golgi localization | 4 |
stable cell | 4 |
adenovirus infection | 4 |
isg ifit | 4 |
remains unclear | 4 |
identified based | 4 |
viral vaccine | 4 |
mhc class | 4 |
coding sequences | 4 |
therapeutic approach | 4 |
envelope structure | 4 |
serial thin | 4 |
deletion mutants | 4 |
rlu well | 4 |
consecutive serial | 4 |
cas system | 4 |
antiviral responses | 4 |
much less | 4 |
intermediate compartment | 4 |
ml ml | 4 |
serine protease | 4 |
pseudovirus system | 4 |
induced fusion | 4 |
reverse primer | 4 |
cytoplasmic extracts | 4 |
calf serum | 4 |
case fatality | 4 |
suppressed doxorubicin | 4 |
therapeutic strategies | 4 |
subsequently incubated | 4 |
dense coat | 4 |
cottontail rabbit | 4 |
eukaryotic libraries | 4 |
ct region | 4 |
protective immunities | 4 |
mucosal immunization | 4 |
protein expressed | 4 |
host membrane | 4 |
slightly reduced | 4 |
leukemia viruses | 4 |
cycle growth | 4 |
becton dickinson | 4 |
hal activation | 4 |
inefficient gene | 4 |
transferred onto | 4 |
nonpermissive temperature | 4 |
bacterial infection | 4 |
eucaryotic ribosomes | 4 |
cell cytopathic | 4 |
abl kinase | 4 |
capsid display | 4 |
mek inhibitor | 4 |
virus containing | 4 |
bv ev | 4 |
proximal aug | 4 |
indicated otherwise | 4 |
mean age | 4 |
virus entirely | 4 |
viral attachment | 4 |
top panel | 4 |
activated protein | 4 |
transcriptional branch | 4 |
pseudotyped vector | 4 |
using mers | 4 |
preclinical studies | 4 |
polyclonal antibody | 4 |
phage display | 4 |
invasive tumor | 4 |
wt cells | 4 |
scale bars | 4 |
chorionic gonadotropin | 4 |
antibodies directed | 4 |
initiate translation | 4 |
favorable immune | 4 |
nl min | 4 |
retrograde transport | 4 |
human epithelial | 4 |
conventional mnt | 4 |
entry depends | 4 |
vlp release | 4 |
blocking buffer | 4 |
interferon induction | 4 |
microdose cytopathic | 4 |
replicative capacity | 4 |
two novel | 4 |
differential translation | 4 |
also indicated | 4 |
eukaryotic mrnas | 4 |
experimental animals | 4 |
cytoplasmic tails | 4 |
strongly induced | 4 |
healthy adults | 4 |
mouse antibody | 4 |
challenge studies | 4 |
culture collection | 4 |
cdna encoding | 4 |
bars denote | 4 |
antibody titres | 4 |
texas red | 4 |
major histocompatibility | 4 |
sha shazip | 4 |
marked reduction | 4 |
visualized using | 4 |
antiviral protection | 4 |
viral pathogens | 4 |
copii coats | 4 |
treatment groups | 4 |
viral transcription | 4 |
significantly suppressed | 4 |
dimensional structures | 4 |
packaging plasmid | 4 |
infectious vesicular | 4 |
enrichment analysis | 4 |
clearly demonstrated | 4 |
activity using | 4 |
viruses isolated | 4 |
experimentally infected | 4 |
vaccine expressing | 4 |
target sequence | 4 |
reporter virus | 4 |
nuclear export | 4 |
doxorubicin promotes | 4 |
human cases | 4 |
might also | 4 |
host gene | 4 |
virus cell | 4 |
enhance transduction | 4 |
pvsv xn | 4 |
persistently infected | 4 |
expressing human | 4 |
trypsin cleavage | 4 |
virus replicates | 4 |
overall translational | 4 |
attenuating mutations | 4 |
cdna clones | 4 |
er membranes | 4 |
complete inhibition | 4 |
gag proteins | 4 |
samples tested | 4 |
administered via | 4 |
pseudotype vectors | 4 |
confer protection | 4 |
barr virus | 4 |
proteins except | 4 |
will require | 4 |
cell activation | 4 |
preproinsulin mrna | 4 |
strongly suggests | 4 |
reference bud | 4 |
beckman sw | 4 |
direct interaction | 4 |
cell populations | 4 |
thermo scientific | 4 |
conserved transcription | 4 |
signal promotes | 4 |
expression led | 4 |
mm dtt | 4 |
glycoproteins gp | 4 |
antiviral mechanism | 4 |
negative plasma | 4 |
antibodies using | 4 |
vitro growth | 4 |
wt wt | 4 |
small size | 4 |
agarose beads | 4 |
primary screen | 4 |
glycoproteins appear | 4 |
virus isolation | 4 |
human chorionic | 4 |
hispidus cells | 4 |
schwannoma cell | 4 |
second protein | 4 |
animals died | 4 |
beetle virus | 4 |
protein subunit | 4 |
plant virus | 4 |
mrnas might | 4 |
mean fluorescence | 4 |
protein ct | 4 |
nearly identical | 4 |
promotes ripa | 4 |
parp levels | 4 |
danger signal | 4 |
susceptible cells | 4 |
ebola viruses | 4 |
control conditions | 4 |
virus dose | 4 |
plaque sizes | 4 |
days later | 4 |
na spike | 4 |
single vaccination | 4 |
fold serially | 4 |
lower panel | 4 |
simplex type | 4 |
cell epitopes | 4 |
moussa virus | 4 |
gml proteins | 4 |
primary cell | 4 |
envelope fusion | 4 |
ferret nv | 4 |
hemagglutinin polypeptide | 4 |
host defense | 4 |
inhibitory action | 4 |
internal membrane | 4 |
baculovirus transduction | 4 |
cellular debris | 4 |
results revealed | 4 |
carbohydrate components | 4 |
specific cellular | 4 |
gml oligomers | 4 |
heterologous viral | 4 |
pestis challenge | 4 |
expression cassette | 4 |
rna species | 4 |
stomatitis disease | 4 |
jersey serotype | 4 |
rna interference | 4 |
four hours | 4 |
poliovirusinfected cells | 4 |
see text | 4 |
methylene chloride | 4 |